Form 4: Orchestra BioMed Holdings Executive Awarded Stock Options and Restricted Stock Units
SEC Form 4 Filing
George Papandreou, General Manager and Senior Vice President at Orchestra BioMed Holdings, received 33,000 stock options and 22,000 restricted stock units on May 8, 2024.
Summary
- On May 8, 2024, George Papandreou, a General Manager and Senior Vice President at Orchestra BioMed Holdings, received compensation in the form of stock options and restricted stock units (RSUs).
- He was awarded 33,000 stock options with an exercise price of $4.98, which become exercisable in installments starting May 8, 2025, and expiring on May 8, 2034.
- Papandreou also received 22,000 RSUs, each representing a contingent right to receive one share of common stock.
- The RSUs vest in installments beginning May 22, 2025, and continuing through May 22, 2028, contingent upon his continued service with the company.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice, indicating confidence in the executive and the company's future prospects. However, it's not a major event that would significantly impact the company's valuation.
Positives
- The granting of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.
- The vesting schedules for both the stock options and RSUs encourage continued service and commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules suggest an expectation of continued service from the executive.
Industry Context
Granting stock options and RSUs is a common practice in the biotech industry to attract, retain, and incentivize key personnel. The specific terms of the grants are likely benchmarked against industry standards and the company's performance.
Comparison to Industry Standards
- Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation plans to align executive interests with shareholder value.
- The vesting schedules and exercise prices are typically determined based on factors such as company performance, industry benchmarks, and individual contributions.
Stakeholder Impact
- Shareholders may view the grant of stock options and RSUs positively, as it aligns executive interests with long-term value creation.
- Employees may see this as a positive sign, indicating the company's commitment to rewarding its key personnel.
Key Dates
| Date | Description |
|---|---|
| 05/08/2024 | Date of transaction: Grant of stock options and RSUs. |
| 05/08/2025 | First vesting date for a portion of the stock options (8,250 options). |
| 08/08/2025 | Second vesting date for a portion of the stock options (24,750 options). |
| 05/08/2034 | Expiration date of the stock options. |
| 05/22/2025 | First vesting date for a portion of the RSUs (3,300 RSUs). |
| 08/22/2025 | Second vesting date for a portion of the RSUs (18,700 RSUs). |
| 05/22/2028 | Final vesting date for the RSUs. |
| 05/10/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.